SynthesisInternational journal of radiation oncology, biology, physics2021
Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response.
Synthesis in International journal of radiation oncology, biology, physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- The Determinants of Toxicity in the Treatment of Prostate Cancer With a Focal, Intraprostatic "Microboost".International journal of radiation oncology, biology, physics · 2025Pooled it
- Prospective validation of stringent dose constraints for prostatic stereotactic radiation monotherapy: results of a single-arm phase II toxicity-oriented trial.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Trial
- Initial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Baseline vulnerability over dosimetric precision: reframing late urinary toxicity after prostate stereotactic body radiotherapy.Translational andrology and urology · 2026Article
- Clinical outcomes of CyberKnife stereotactic radiotherapy for localized prostate cancer: comparison of 35 Gy in 5 fractions and 36 Gy in 4 fractions.Journal of radiation research · 2026Article
- The Kilovoltage Intrafraction Monitoring Real-Time Prostate Cancer Image Guided Radiation Therapy Technology Journey: From Clinical Trials to Your Clinic.International journal of radiation oncology, biology, physics · 2026Article
- Association of Perirectal Hydrogel Spacer Placement with Clinical Outcomes in Patients with Prostate Cancer Undergoing Radiotherapy: A Systematic Review and Meta-Analysis.The world journal of men's health · 2026Article
- Impact of intra- and interfractional motion on the dose distribution and urinary adverse events for magnetic resonance-guided prostate cancer radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Pre-PROTO-PRIME: stereotactic body proton therapy to the prostate and pelvic nodes for high-risk and node-positive prostate cancer - feasibility, acute toxicity and dosimetric insights.Clinical and translational radiation oncology · 2026Article
- Sharing a flexible urethral sparing SBRT prostate RapidPlan model and quantifying plan quality via dosimetric scorecard with clinical implementation.Radiation oncology (London, England) · 2025Article
- Impact of intrafraction fiducial tracking on planning target margins during prostate stereotactic body radiotherapy using Brainlab ExacTrac Dynamic with robotic couch correction.Journal of applied clinical medical physics · 2025Article
- Urethral and bladder dosimetry and urinary toxicity in prostate cancer patients undergoing SBRT with and without intra-prostatic boost.Clinical and translational radiation oncology · 2025Article
- Stereotactic Body Radiosurgery Associated With Rectal Displacement using Gelfoam for Sacral Chordomas: Preliminary Report of 3 Cases.Advances in radiation oncology · 2025Article
- Unmasking enteritis: reply to commentary titled "Clarifying Gastrointestinal toxicity attribution in WP-SBRT: A commentary on Dinesan et al. and proposal of a bladder-bowel displacement index".Clinical and translational radiation oncology · 2025Article
- Toxicity profile and clinical outcomes of stereotactic body radiotherapy with a focal boost without fiducials or perirectal hydrogel spacer for localized prostate cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Predicting acute and late toxicity in prostate cancer stereotactic ablative radiotherapy: the role of dosimetric parameters and prostate volume.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Using deep learning generated CBCT contours for online dose assessment of prostate SABR treatments.Journal of applied clinical medical physics · 2025Article
- Acute enteritis with pelvic SBRT: Influence of bowel delineation methods.Clinical and translational radiation oncology · 2025Article
- Investigation of pelvic floor influence on prostate displacement in image-guided radiotherapy.The Prostate · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 1 country.
Funding
Abstract
purposeUltrahypofractionationed radiation therapy for prostate cancer is increasingly studied and adopted. The American Association of Physicists in Medicine Working Group on Biological Effects of Hypofractionated Radiotherapy therefore aimed to review studies examining toxicity and quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer and model its effect. METHODS AND MATERIALS: We performed a systematic PubMed search of prostate SBRT studies published between 2001 and 2018. Those that analyzed factors associated with late urinary, bowel, or sexual toxicity and/or quality of life were included and reviewed. Normal tissue complication probability modelling was performed on studies that contained detailed dose/volume and outcome data.
resultsWe found 13 studies that examined urinary effects, 6 that examined bowel effects, and 4 that examined sexual effects. Most studies included patients with low-intermediate risk prostate cancer treated to 35-40 Gy. Most patients were treated with 5 fractions, with several centers using 4 fractions. Endpoints were heterogeneous and included both physician-scored toxicity and patient-reported quality of life. Most toxicities were mild-moderate (eg, grade 1-2) with a very low overall incidence of severe toxicity (eg, grade 3 or higher, usually <3%). Side effects were associated with both dosimetric and non-dosimetric factors.
conclusionsProstate SBRT appears to be overall well tolerated, with determinants of toxicity that include dosimetric factors and patient factors. Suggested dose constraints include bladder V(Rx Dose)Gy <5-10 cc, urethra Dmax <38-42 Gy, and rectum Dmax <35-38 Gy, though current data do not offer firm guidance on tolerance doses. Several areas for future research are suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.